These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12083844)

  • 21. Paramyxovirus mediated cell fusion requires co-expression of both the fusion and hemagglutinin-neuraminidase glycoproteins.
    Heminway BR; Yu Y; Galinski MS
    Virus Res; 1994 Jan; 31(1):1-16. PubMed ID: 8165862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
    Mason JN; Elbahesh H; Russell CJ
    J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
    Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
    PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic characteristics of human parainfluenza viruses 1-4 associated with acute lower respiratory tract infection in Chinese children, during 2015-2021.
    Zhu Y; Sun Y; Li C; Lu G; Jin R; Xu B; Shang Y; Ai J; Wang R; Duan Y; Chen X; Xie Z
    Microbiol Spectr; 2024 Oct; 12(10):e0343223. PubMed ID: 39264196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
    Tang RS; Schickli JH; MacPhail M; Fernandes F; Bicha L; Spaete J; Fouchier RA; Osterhaus AD; Spaete R; Haller AA
    J Virol; 2003 Oct; 77(20):10819-28. PubMed ID: 14512532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An oligosaccharide at the C-terminus of the F-specific domain in the stalk of the human parainfluenza virus 3 hemagglutinin-neuraminidase modulates fusion.
    Wang Z; Mirza AM; Li J; Mahon PJ; Iorio RM
    Virus Res; 2004 Feb; 99(2):177-85. PubMed ID: 14749183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
    Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
    Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
    Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Characteristics of Human Parainfluenza Virus Types 1-4 From Patients With Clinical Respiratory Tract Infection in China.
    Shao N; Liu B; Xiao Y; Wang X; Ren L; Dong J; Sun L; Zhu Y; Zhang T; Yang F
    Front Microbiol; 2021; 12():679246. PubMed ID: 34335501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue.
    Palmer SG; Porotto M; Palermo LM; Cunha LF; Greengard O; Moscona A
    mBio; 2012; 3(3):. PubMed ID: 22669629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
    Tao T; Skiadopoulos MH; Davoodi F; Surman SR; Collins PL; Murphy BR
    Vaccine; 2001 Jun; 19(27):3620-31. PubMed ID: 11395195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
    Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins.
    Stope MB; Karger A; Schmidt U; Buchholz UJ
    J Virol; 2001 Oct; 75(19):9367-77. PubMed ID: 11533200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies.
    Suryadevara N; Otrelo-Cardoso AR; Kose N; Hu YX; Binshtein E; Wolters RM; Greninger AL; Handal LS; Carnahan RH; Moscona A; Jardetzky TS; Crowe JE
    Nat Microbiol; 2024 Aug; 9(8):2128-2143. PubMed ID: 38858594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lentiviral vectors pseudotyped with envelope glycoproteins derived from human parainfluenza virus type 3.
    Jung C; Grzybowski BN; Tong S; Cheng L; Compans RW; Le Doux JM
    Biotechnol Prog; 2004; 20(6):1810-6. PubMed ID: 15575716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.